Protagonist Ther - PTGX STOCK NEWS

Protagonist Therapeutics (Nasdaq:PTGX) announced on October 31, 2020 that it granted an inducement award to Nora Boyer, its newly appointed Vice President of Medical Affairs. The award includes an option to purchase 40,000 shares at an exercise price of $18.95, the closing price on October 30, 2020. Shares will vest over a four-year period, with 25% vesting after one year. This grant complies with NASDAQ Marketplace Rule 5635(c)(4>. Protagonist develops peptide-based therapeutics for unmet medical needs, with three clinical-stage assets including PTG-300 and PTG-200.

Protagonist Therapeutics (NASDAQ: PTGX) announced the progression of two new oral peptide IL-23 receptor antagonists, PN-235 and PN-232, into clinical development as part of its collaboration with Janssen Biotech. These additions complement PTG-200, which is in a Phase 2 study for Crohn's disease. The company aims to leverage these candidates for multiple indications, anticipating the initiation of a Phase 1 study for PN-235 by 2020's fourth quarter. The partnership allows Protagonist to receive milestone payments while Janssen oversees further development.

Protagonist Therapeutics (NASDAQ:PTGX) announced that the European Medicines Agency granted orphan drug designation for PTG-300, aimed at treating polycythemia vera. This synthetic peptide mimetic of hepcidin also received similar designation from the FDA. The company is moving forward with a Phase 2 clinical trial and anticipates launching a pivotal study in mid-2021. Polycythemia vera affects about 100,000 patients in the U.S. and EU, underscoring the need for effective treatments. Orphan drug designation provides advantages for clinical development.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) will participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit on September 23, 2020, at 8 a.m. EDT. Dinesh V. Patel, Ph.D., the company's President and CEO, will engage in a fireside chat during the event. A live and archived webcast will be available via this link and on the Protagonist website. Protagonist focuses on novel peptide-based therapeutics for unmet medical needs, with three clinical-stage assets including PTG-300 and PTG-200.

Protagonist Therapeutics (Nasdaq:PTGX) announced on September 15, 2020, the issuance of an inducement award to Matthew Gosling, the newly appointed Executive Vice President and General Counsel. This award includes an option to purchase 100,000 shares of common stock at an exercise price of $21.66, matching the stock's closing price on the grant date. The shares will vest over four years, with the first 25% vesting after one year. The award is part of Mr. Gosling's employment terms approved by the company's compensation committee.

Protagonist Therapeutics (NASDAQ: PTGX) has announced that its CEO, Dinesh V. Patel, Ph.D., will engage in a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 11 a.m. EDT. The event will be available via live and archived webcast on the company's investor website. Protagonist Therapeutics focuses on developing novel peptide-based therapeutics, with three clinical-stage assets: PTG-300 for blood disorders, PTG-200 for inflammatory bowel disease, and PN-943 also targeting inflammatory bowel disease.

Protagonist Therapeutics (NASDAQ:PTGX) will host a webinar on Sept. 11, 2020, from 12 p.m. to 1:30 p.m. EDT, titled "PTG-300 Opportunity Update". The event will discuss clinical needs in polycythemia vera and market research for PTG-300, an injectable hepcidin mimetic aimed at treating blood disorders. Presenters include Dr. Ronald Hoffman from the Icahn School of Medicine and Dr. Srdan Verstovsek from MD Anderson Cancer Center. The webinar will be accessible online and archived afterward for future viewing.

Protagonist Therapeutics (Nasdaq:PTGX) has appointed Sarah O'Dowd as an independent director on its Board, enhancing its governance with her extensive experience in the biopharmaceutical sector. O'Dowd's previous roles include key positions at Lam Research and FibroGen. She replaces Chaitan Khosla, who is stepping down. CEO Dinesh V. Patel emphasized her strategic expertise as vital for Protagonist's growth, particularly with its clinical assets focused on hematology/oncology and inflammatory bowel diseases. O'Dowd expressed eagerness to contribute to Protagonist's vision during this growth phase.

Protagonist Therapeutics (PTGX) reported its Q2 2020 financial results, highlighting significant advancements in its clinical programs. The company moved three candidates into Phase 2 trials, including PTG-300 for polycythemia vera and two oral candidates for inflammatory bowel disease. Financially, PTGX raised $122 million through a secondary offering and has sufficient resources to fund operations through mid-2023. The net loss for Q2 was $19.4 million, improving from $29.2 million the previous year. Revenue from collaborations rose to $6.2 million this quarter, compared to a loss in revenue last year.